A Phase 1/2 interventional study of SD-101(1) and Pembrolizumab in Metastatic Melanoma and Head Neck Cancer, sponsored by Dynavax Technologies Corporation. Terminated at 47 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-03.
Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.
Among the 2,050 studies in Melanoma with a site in United States, this one is the 202nd largest by enrollment of the 1,750 interventional ones that give a count, is one of 108 that started in 2015, is one of 287 in phase 1/2, and was the 1,121st registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States
Ages up to 25
John Kirkwood · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,050 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 935 · Phase 2 907 · Phase 3 115 · Phase 4 11
First in 1991; this study’s year is marked. 108 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 37 across the 1,750 interventional studies, 156 across the 212 observational. Of the 1,484 that completed or were terminated, 598 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
801 of 2,050 have an industry lead sponsor. The 10 most frequent:
This study is registered under Dynavax Technologies Corporation, one of the names counted as Sanofi. Under that name alone:
Dynavax Technologies Corporation is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Sanofi has 8 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
138 of the studies in Melanoma with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 138 to your calendar (.ics) → With an account.
Among the 2,050 studies in Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in patients with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
This study will be conducted in 2 phases. Phase 1 evaluates SD-101 given in combination with pembrolizumab in melanoma populations (anti-PD-1/L1 naïve and anti-PD-1/L1 experienced with progressive disease) in up to 4 Dose Escalation cohorts to identify a recommended Phase 2 dose (RP2D) to be evaluated in up to 4 Dose Expansion cohorts in Phase 2. Phase 2 also includes up to 4 Dose Expansion cohorts of patients with HNSCC (anti-PD-1/L1 naïve and anti-PD-1/L1 experienced with progressive disease).
[Inclusion Criteria (Phase 1 and Phase 2)]
Patient must have adequate organ function as indicated by the following laboratory values:
Hematological:
Renal:
Hepatic:
Coagulation:
Female patients of , as defined in Section 5.2.1, must have a negative urine or serum pregnancy test within 72 hours prior to taking the first dose of trial treatment. If the urine test is positive or cannot be confirmed as negative then a serum test is required which must be negative for the patient to enroll. Women of childbearing potential (WOCBP) must be willing to use 2 medically acceptable methods of from Day 1 through 120 days after the last dose of trial treatment. The 2 medically acceptable birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), copper intrauterine device, sponge, or spermicide as per local regulations or guidelines. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).
Male patients of , as described in Section 5.2.1, must agree to use an adequate method of contraception from Day 1 through 120 days after the last dose of trial treatment.
Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
[Inclusion Criteria (Phase 1 only: Melanoma)]
For Phase 1 Escalation Cohorts 1-4, must have at least 1 lesion that qualifies as a target lesion per v1.1 except for the minimum measurement of 10 mm in diameter for superficial lesions, is easily accessible (palpable or can be visualized by ultrasound), and is amenable to multiple intratumoral injections. If superficial, the target lesion must be documented photographically.
[Inclusion Criteria (Phase 2 only: Melanoma)]
Expansion Cohort 8: Must have all of the following:
[Inclusion Criteria (Phase 2 only: HNSCC)]
Expansion Cohort 7: Must have all of the following:
[Exclusion Criteria (Phase 1 and Phase 2)]
Has not recovered to Grade 1 or better from the AEs due to cancer therapeutics prior to study enrollment
NOTE: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia or Grade 2 AEs that qualify as Grade 2 due to replacement hormonal or therapy are exceptions to this criterion and may qualify for the study with approval by a Dynavax Medical Monitor.
If a patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to enrollment.
Known active central nervous system metastases or carcinomatous meningitis
NOTE: Patients with previously treated may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of trial treatment and with any neurologic symptoms returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
Any known additional that is progressing or requires active treatment. Exceptions are cutaneous melanoma or HNSCC under study per protocol, or basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy.
[Exclusion Criteria (Phase 2, Melanoma Expansion Cohorts 1 and 5 only)]
Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
[Exclusion Criteria (Phase 2, Melanoma Expansion Cohorts 2 and 8 only)]
Any prior combination therapy involving agents given by intratumoral injection that target the innate immune pathway or system such as oncolytic viral or microbial therapy (eg, T-VEC [talimogene laherparepvec]), toll-like receptors (TLR) agonists, STING or RIG-1 and an anti-PD-1/L1 inhibitor
[Exclusion Criteria (Phase 2, HNSCC Expansion Cohorts 3 and 6 only)]
Require anticoagulation therapy
[Exclusion Criteria (Phase 2, HNSCC Expansion Cohorts 4 and 7 only)]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).
Drug: SD-101(1) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
Drug: SD-101(2) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
Drug: SD-101(2) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
Drug: SD-101(2) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
Drug: SD-101(2) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
Biological: SD-101(3) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
Biological: SD-101(3) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.
Biological: SD-101(3) · Biological: Pembrolizumab
Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.
Biological: SD-101(3) · Biological: Pembrolizumab
SD-101 administered intratumorally at escalating doses (up to 11 doses).
Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
Phase 1 Dose Escalation Only - Number of Participants With DLTs
Dose-limiting toxicities (DLTs) are defined per protocol as specific AEs occurring from the time of the first injection (Day 1) through Day 29.
Time frame: Day 1 through Day 29
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group
Overall response rate (ORR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
Time frame: Day 1 through Day 743
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group
Time to objective response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
Time frame: Day 1 through Day 743
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group
Duration of response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
Time frame: Day 1 through Day 743
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group
Disease Control Rate (DCR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
Time frame: Day 1 through Day 743
Phase 1 Dose Escalation and Phase 2 Dose Expansion - Progression-Free Survival Rate by Analysis Group
Progression-Free Survival (PFS) rate by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
Time frame: Day 1 through Day 743
| Milestone | SD-101 1 mg | SD-101 2 mg | SD-101 4 mg | SD-101 8 mg | SD-101 8 mg in Anti-PD-1/L1-Naïve Melanoma | SD-101 8 mg in Anti-PD-1/L1-Experienced Melanoma | SD-101 8 mg in Anti-PD-1/L1-Naïve HNSCC | SD-101 8 mg in Anti-PD-1/L1-Experienced HNSCC | SD-101 2 mg in Anti-PD-1/L1-Naïve Melanoma | SD-101 2 mg in Anti-PD-1/L1-Naïve HNSCC | SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCC | SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 5 | 5 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed sd-101 treatment (up to 11 doses) | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 4 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 3 | 2 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SD-101 1 mg | SD-101 2 mg | SD-101 4 mg | SD-101 8 mg | SD-101 8 mg in Anti-PD-1/L1-Naïve Melanoma | SD-101 8 mg in Anti-PD-1/L1-Experienced Melanoma | SD-101 8 mg in Anti-PD-1/L1-Naïve HNSCC | SD-101 8 mg in Anti-PD-1/L1-Experienced HNSCC | SD-101 2 mg in Anti-PD-1/L1-Naïve Melanoma | SD-101 2 mg in Anti-PD-1/L1-Naïve HNSCC | SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCC | SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 57 | 25 | 23 | 9 | 24 | 28 | 23 | 30 |
| Completed sd-101 treatment (up to 11 doses) | 0 | 0 | 0 | 0 | 25 | 7 | 3 | 2 | 9 | 5 | 1 | 11 |
| Completed sd-101 treatment cycle 2 (up to 22 doses) | 0 | 0 | 0 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 52 | 25 | 23 | 9 | 22 | 28 | 23 | 30 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 5 | 1 | 1 | 0 | 1 | 1 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 11 | 2 | 0 | 1 | 5 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 22 | 18 | 17 | 7 | 5 | 17 | 17 | 21 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 1 | 5 | 2 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 10 | 3 | 2 | 0 | 10 | 5 | 1 | 7 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Dose-limiting toxicities (DLTs) are defined per protocol as specific AEs occurring from the time of the first injection (Day 1) through Day 29.
| Participants | SD-101 1 mg | SD-101 2 mg | SD-101 4 mg | SD-101 8 mg | SD-101 8 mg in Anti-PD-1/L1-Naïve Melanoma | SD-101 8 mg in Anti-PD-1/L1-Experienced Melanoma | SD-101 8 mg in Anti-PD-1/L1-Naïve HNSCC | SD-101 8 mg in Anti-PD-1/L1-Experienced HNSCC | SD-101 2 mg in Anti-PD-1/L1-Naïve Melanoma | SD-101 2 mg in Anti-PD-1/L1-Naïve HNSCC | SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCC | SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 Dose Escalation Only - Number of Participants With DLTs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Overall response rate (ORR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
| Participants | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg |
|---|---|---|---|---|---|---|---|---|
| Complete Response | 9 | 4 | 0 | 1 | 2 | 0 | 0 | 1 |
| Partial Response | 25 | 16 | 7 | 3 | 4 | 6 | 2 | 0 |
| Stable Disease | 2 | 8 | 8 | 8 | 7 | 5 | 3 | 2 |
| Progressive Disease | 5 | 8 | 12 | 11 | 10 | 9 | 10 | 4 |
| Not Evaluable | 4 | 5 | 4 | 7 | 5 | 3 | 8 | 2 |
Time to objective response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
| months | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg |
|---|---|---|---|---|---|---|---|---|
| Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group | 3.2 ± 1.6 | 4.1 ± 2.96 | 5.1 ± 3.06 | 4.3 ± 2.98 | 2.3 ± .92 | 2.4 ± 0.87 | 2.7 ± 1.09 | 2.1 ± 0 |
Duration of response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
| months | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg |
|---|---|---|---|---|---|---|---|---|
| Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group | 11.1 ± 6.42 | 11.7 ± 5.96 | 4.6 ± 6.57 | 7.6 ± 7.28 | 5.9 ± 4.93 | 6.3 ± 3.96 | 2.1 ± 0.07 | 8.1 ± 0 |
Disease Control Rate (DCR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
| Participants | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg |
|---|---|---|---|---|---|---|---|---|
| Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group | 36 | 28 | 15 | 12 | 13 | 11 | 5 | 3 |
Progression-Free Survival (PFS) rate by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).
| percentage of participants | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg |
|---|---|---|---|---|---|---|---|---|
| 3 months | 85.7 (70.9 to 93.3) | 71.9 (54 to 83.8) | 46.7 (28.4 to 63) | 48 (27.8 to 65.6) | 46.4 (26.6 to 64.1) | 43.5 (23.3 to 62.1) | 31.6 (12.9 to 52.2) | 37.5 (8.7 to 67.4) |
| 6 months | 78.4 (62.6 to 88.1) | 63.3 (45.2 to 76.8) | 33 (17.2 to 49.8) | 24 (9.8 to 41.7) | 26.5 (10.5 to 45.7) | 17.4 (5.4 to 35) | 0 (0 to 0) | 25 (3.7 to 55.8) |
| 9 months | 70.8 (54.3 to 82.3) | 60.4 (42.4 to 74.4) | 21.4 (8.6 to 37.9) | 14.4 (3.9 to 31.4) | 21.2 (7.1 to 40.3) | 17.4 (5.4 to 35) | 0 (0 to 0) | 12.5 (0.7 to 42.3) |
| 12 months | 70.8 (54.3 to 82.3) | 53.7 (35.7 to 68.7) | 21.4 (8.6 to 37.9) | 9.6 (1.7 to 25.7) | 15.9 (4.2 to 34.4) | 8.7 (1.5 to 24.2) | 00 (0 to 0) | 0 (0 to 0) |
| 15 months | 65.1 (48.2 to 77.8) | 49.9 (31.9 to 65.5) | 0 (0 to 0) | 9.6 (1.7 to 25.7) | 15.9 (4.2 to 34.4) | 4.3 (0.3 to 18.2) | 00 (0 to 0) | 0 (0 to 0) |
| 18 months | 61.5 (44 to 75) | 40.3 (22.3 to 57.7) | 0 (0 to 0) | 9.6 (1.7 to 25.7) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| 21 months | 61.5 (44 to 75) | 40.3 (22.3 to 57.7) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| 24 months | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
Collected over From informed consent through Day 743. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | 2/44 (4.5%) | 15/44 (34.1%) | 44/44 (100%) |
| Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | 3/39 (7.7%) | 17/39 (43.6%) | 39/39 (100%) |
| Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | 5/31 (16.1%) | 6/31 (19.4%) | 31/31 (100%) |
| Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | 7/30 (23.3%) | 9/30 (30%) | 30/30 (100%) |
| HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | 6/27 (22.2%) | 8/27 (29.6%) | 25/27 (92.6%) |
| HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | 13/23 (56.5%) | 5/23 (21.7%) | 23/23 (100%) |
| HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | 7/23 (30.4%) | 10/23 (43.5%) | 22/23 (95.7%) |
| HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | 3/9 (33.3%) | 4/9 (44.4%) | 9/9 (100%) |
| Event | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg |
|---|---|---|---|---|---|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/44 | 0/39 | 0/31 | 0/30 | 0/27 | 0/23 | 0/23 | 1/9 |
| CellulitisInfections and infestations | 2/44 | 0/39 | 0/31 | 0/30 | 1/27 | 0/23 | 0/23 | 1/9 |
| Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/44 | 0/39 | 0/31 | 1/30 | 0/27 | 0/23 | 0/23 | 1/9 |
| Ischaemic strokeNervous system disorders | 0/44 | 0/39 | 0/31 | 0/30 | 0/27 | 0/23 | 0/23 | 1/9 |
| Respiratory depressionRespiratory, thoracic and mediastinal disorders | 0/44 | 0/39 | 0/31 | 0/30 | 0/27 | 0/23 | 0/23 | 1/9 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/44 | 0/39 | 0/31 | 0/30 | 0/27 | 0/23 | 0/23 | 1/9 |
| PneumoniaInfections and infestations | 0/44 | 1/39 | 1/31 | 3/30 | 2/27 | 1/23 | 1/23 | 0/9 |
| MalnutritionMetabolism and nutrition disorders | 0/44 | 0/39 | 0/31 | 0/30 | 1/27 | 0/23 | 2/23 | 0/9 |
| DehydrationMetabolism and nutrition disorders | 0/44 | 3/39 | 0/31 | 1/30 | 1/27 | 1/23 | 0/23 | 0/9 |
| SepsisInfections and infestations | 2/44 | 0/39 | 0/31 | 0/30 | 2/27 | 1/23 | 1/23 | 0/9 |
| Event | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg |
|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 33/44 | 31/39 | 13/31 | 22/30 | 15/27 | 17/23 | 7/23 | 5/9 |
| HeadacheNervous system disorders | 23/44 | 25/39 | 9/31 | 14/30 | 3/27 | 10/23 | 2/23 | 4/9 |
| ChillsGeneral disorders | 19/44 | 20/39 | 6/31 | 16/30 | 3/27 | 10/23 | 2/23 | 1/9 |
| MyalgiaMusculoskeletal and connective tissue disorders | 18/44 | 17/39 | 2/31 | 16/30 | 1/27 | 9/23 | 1/23 | 2/9 |
| MalaiseGeneral disorders | 14/44 | 20/39 | 4/31 | 11/30 | 0/27 | 0/23 | 2/23 | 2/9 |
| DiarrhoeaGastrointestinal disorders | 21/44 | 11/39 | 6/31 | 7/30 | 2/27 | 7/23 | 0/23 | 0/9 |
| PyrexiaGeneral disorders | 10/44 | 15/39 | 7/31 | 7/30 | 6/27 | 6/23 | 6/23 | 4/9 |
| Injection site erythemaGeneral disorders | 17/44 | 9/39 | 4/31 | 13/30 | 1/27 | 4/23 | 2/23 | 1/9 |
| NauseaGastrointestinal disorders | 13/44 | 15/39 | 9/31 | 10/30 | 8/27 | 8/23 | 0/23 | 0/9 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/44 | 8/39 | 3/31 | 4/30 | 0/27 | 0/23 | 0/23 | 0/9 |
The intent-to-treat (ITT) population comprises all participants who received at least one dose of SD-101. Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101, as specified by the statistical analysis plan. Participants who received 1 mg or 4 mg of SD-101 in Phase 1: Dose Escalation of the study are not included in the analysis groups.
| Age, Categorical(Participants) | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 18 | 13 | 17 | 16 | 10 | 15 | 4 | 109 |
| >=65 years | 29 | 23 | 18 | 13 | 12 | 13 | 8 | 5 | 121 |
| Age, Continuous(years) | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.2 ± 13.34 | 65.3 ± 12.44 | 65.6 ± 12.99 | 62.4 ± 15.25 | 62.6 ± 10.66 | 67.2 ± 9.59 | 61.0 ± 12.94 | 65.2 ± 12.35 | 64.4 ± 12.45 |
| Sex: Female, Male(Participants) | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 13 | 14 | 10 | 7 | 9 | 2 | 8 | 1 | 64 |
| Male | 32 | 27 | 21 | 23 | 19 | 21 | 15 | 8 | 166 |
| Ethnicity (NIH/OMB)(Participants) | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 4 | 0 | 0 | 2 | 1 | 10 |
| Not Hispanic or Latino | 43 | 37 | 28 | 26 | 28 | 22 | 20 | 8 | 212 |
| Unknown or Not Reported | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 8 |
| Race/Ethnicity, Customized(Participants) | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 44 | 41 | 30 | 25 | 24 | 20 | 19 | 9 | 212 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 5 |
| Asian | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 0 | 7 |
| Other | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 6 |
| ECOG Performance Status(Participants) | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28 | 30 | 19 | 16 | 5 | 6 | 4 | 2 | 110 |
| 1 | 17 | 11 | 12 | 14 | 23 | 17 | 19 | 7 | 120 |
| PDL1 Expression(Participants) | Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg | Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg | Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg | HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg | HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Positive | 21 | 13 | 9 | 13 | 14 | 15 | 4 | 7 | 96 |
| Negative | 14 | 15 | 8 | 11 | 2 | 4 | 5 | 1 | 60 |
| Unknown | 10 | 13 | 14 | 6 | 12 | 4 | 14 | 1 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data will be shared under guidance of the New Rule - FDAAA 801 eff. Jan 2017. 3/2017 - additional changes forthcoming.
The record gives a start of Sep 2015, a primary completion of Apr 2020 and a completion of Apr 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nelitolimod
Dynavax Technologies Corporation →